Accelerate your product development.


Our Regenerative Medicine pre-clinical services cover planning and execution of in-vitro biological testing and in-vivo animal testing. We work with sponsors to focus preclinical studies on establishing and reinforcing a therapy’s putative mechanism of action, evidence of efficacy, proof of concept, and safety. Our aim is to help build a preclinical data package to prepare the therapy for human clinical study, and confidence that the therapeutic effect is superior to the current standard of care.

We offer comprehensive services that are designed to address sponsor pre-clinical needs from product characterization to pre-clinical safety testing and elucidation of probable mechanism of action. Biological testing capabilities encompass a range of cell and molecular biological assays that help enable the development and characterization of ancillary products and novel therapeutics.  We work with researchers and manufacturers to evaluate and select therapy-enabling technologies they can depend on from early stage discovery through pre-clinical development and commercial application.

Services include:

  • Process improvement
  • Concept development and proof-of-concept
  • Protein characterization
  • Bioassay development (e.g., potency, purity, identity)

The following examples were selected from completed studies (published and unpublished data) and illustrate our range of biological testing capabilities.

Study to assess the ability of MSCs to differentiate and synthesize cartilage matrix. Histological sections were stained with Alcian blue and Sirus red to assess hyaline cartilage-like tissue in pellets.

Project to compare MSCs grown in different media supplements and the effect on their ability to immunomodulate activated PBMCs.

Study to demonstrate the unique and reproducible features of T-cells grown with different media supplements.

Pre-clinical animal studies are supported by operators experienced in minimally invasive and surgical procedures to test a range of clinical indications in a variety of small and large animal species. We work with sponsors on animal and disease/injury model selection, ensuring the biological response is similar to humans. We are also able to address the inherent limitations of the animal model, the physiological and anatomical constraints, and the inherent variability of the model.

The following examples were selected from completed animal studies to evaluate mechanism of action for novel therapeutic candidates and new devices to support improved routes of delivery for cell and gene therapy products.

MicroCT images from a rodent hind limb implantation study, designed to assess the osteoinductive potential of a bone filling material with and without pro-osteogenic agents.

Study to evaluate candidate injectable treatments for primary knee OA, in a Dunkin-Hartley guinea pig model. Images shown cover ultrasound guided administration of the injectable to the knee joint, microCT examination of the subchondral bone, MRI imaging for quantitation of proteoglycan in cartilage, and histology to assess cartilage degeneration.

Demonstration of coronary sinus retrograde delivery of fluorescent labelled cells in a porcine heart failure model.


Rodenberg EJ, Patel DS, Shirley B, Young BW, Taylor AF, Steidinger HR, Fisher SJ, Patel AN. Catheter-based retrograde coronary sinus infusion is a practical delivery technique for introducing biological molecules into the cardiac system. Catheterization and Cardiovascular Interventions, 2019.

Canestrari E, Steidinger HR, McSwain B, Charlebois SJ, Dann CT. Human Platelet Lysate Media Supplement Supports Lentiviral Transduction and Expansion of Human T Lymphocytes While Maintaining Memory Phenotype. Journal of Immunology Research, 2019.

Thompson S, Klarer A, Smith D, Charlebois S, Steidinger H, Taylor A. Improving the quality cell yield of T-cell immunotherapies through selective pressures imparted by culture media supplements. Cell & Gene Therapy Insights 2020; 6(2), 287–294.

Charlebois SJ, Canestrari E, Harris S. Characterization of a pathogen reduced human platelet lysate. Cytotherapy, Volume 20, Issue 5, Page S61, May 2018.

Canestrari E, Charlebois SJ, Harris S. Human platelet lysate as a media supplement for ex vivo expansion of immune cells. Cytotherapy, Volume 20, Issue 5, Page S61, May 2018.

Charlebois SJ, Ramachandran N, Hiles MC, McRoy W, Poderycki M, Steidinger H, Kuske J. Design verification and enhanced risk mitigation tests for cytocompatibility evaluation of cell delivery devices. Cytotherapy, Volume 16, Issue 4, Page S48, April 2014.